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México. 7Cancerology’s National Institute, México, Distrito Federal, México. 8Angeles Mocel Hospital, Siglo XXI, México,
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Concise summaries
• There is good evidence supporting the efficacy
and safety of endoscopic treatment (photo-
dynamic therapy (PDT), RFA, endoscopic
resection (ER)) in early Barrett’s cancer. The
role of endoscopic treatment for those with no
dysplasia or low-grade dysplasia (LGD) is un-
certain and cannot be uniformly recommended
at this time.
• The current optimal approach for endoscopic
management of early Barrett’s cancer is ER
of visible mucosal lesions followed by eradi-
cation of any residual Barrett’s mucosa with
RFA.
• It is not clear if ablative therapies reduce cancer
risk. In susceptible BE patients, they may induce
formation of cells with damaged DNA and mu-
tations and thus with higher risk to develop
esophageal adenocarcinoma (EAC). Additional
markers that have been reported to be abnor-
mal in Barrett’s intestinal metaplasia and EAC
deserve to be studied.
• The most recent devices launched in the field of
endoluminal plication procedures allow for the
creation of a valve that resembles a laparoscopic
fundoplication with a high-pressure zone and
interesting anatomical appearance.
• Argon plasma coagulation (APC), at a power
output of 60–90 W, allows a safe ablation of
BE and LGD with a high success rate. In most
series of patients treated with APC, the newly
developed squamous epithelium remains stable
at up to five-year follow-up.
• Radiofrequency ablation (RFA) seems optimal
for treating flat, nonnodular Barrett’s esophagus
(BE). Nodular disease may be treated with RFA
following the removal of the nodular segments
with endoscopic mucosal resection. Proof of
true cancer reduction with implementation of
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RFA as a treatment strategy in nondysplastic BE
is still lacking.
• Banding without-resection (BWR) is a new
ablation modality that probably collects the
desired criteria for a simple and effective ab-
lative technique for BE. BWR has some advan-
tages and may have fewer risks than EMR and
other ablative modalities because it is minimally
invasive.
• The factors of recurrence of Barrett’s mu-
cosa after ablation cannot be defined yet, but
the difference between recurrence and hidden
residual Barrett’s mucosa has to be defined
first.
• It has been shown that the addition of an an-
tireflux operation, most typically a laparoscopic
Nissen fundoplication, reduces the rate of recur-
rent or persistent BE.
1. What are the current indications and




The role of endoscopic therapy in BE has evolved.
Once considered experimental for high-grade dys-
plasia (HGD), it is now becoming established as the
treatment of choice in that setting. The indications
for endoscopic therapy in BE are summarized in
Table 1.
Endoscopic therapies available include ER, RFA,
photodynamic therapy (PDT), cryotherapy, and
other modalities such as APC, multipolar electro-
cautery, and laser therapy. There is good evidence
supporting the efficacy and safety of endoscopic
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treatment (PDT, RFA, and ER) in early Barrett’s
cancer. The role of endoscopic treatment for those
with no dysplasia or LGD is uncertain and cannot
be uniformly recommended at this time.
Endoscopic resection
ER is superior to mucosal biopsies for diagnosis and
staging of dysplasia, changing the initial histologic
diagnosis and management in about 25% of cases.1
ER is an excisional therapy, allowing for removal of
visible neoplastic mucosal lesions. Negative margins
obtained with ER correlate with surgical pathology.
Importantly, there is a low rate (<3%) of lymph
node metastases with mucosal neoplasia (intramu-
cosal carcinoma).2 Following ER, metachronous
lesions develop in approximately 20% during
follow-up.3
Ablation
The only modalities studied in controlled fashion for
early Barrett’s cancer are PDT and RFA (Table 2).
Both were superior to medical therapy in eradica-
tion of HGD and decreased progression to cancer.
Stricture rate was higher with PDT than RFA.
Multimodality therapy
The current optimal approach for endoscopic man-
agement of early Barrett’s cancer is ER of visible
mucosal lesions followed by eradication of any resid-
ual Barrett’s mucosa, with RFA being the ablative
procedure of choice. Table 3 below summarizes the
prospective studies evaluating multimodality ther-
apy, highlighting an efficacy of over 90% in eradica-
tion of dysplasia and Barrett’s mucosa with relatively
low complication rates (13–17%).
Recommendations
Endoscopically visible mucosal lesions are removed
with ER, allowing for accurate staging and poten-
tially curative excision of the mucosal neoplasia. ER
Ann. N.Y. Acad. Sci. 1232 (2011) 140–155 c© 2011 New York Academy of Sciences. 141
Barrett’s esophagus: endoscopic treatments I Saunders et al.
Table 2. Summary results for endoluminal plication devices
PDT (n = 138) RFA (n = 42)
Author Overholt et al.5 Shaheen et al.6
Medical therapy Omeprazole 20 mg BID Esomeprazole 40 mg BID
Nodular disease 33%, additional 50 J/cm PDT 9%, EMR allowed prior to study entry
Ablation treatments Mean 2.3 Mean 3.5
Follow-up 24 months 12 months
Eradication of IM 52% vs. 7% 74% vs. 2.3%
Eradication of HGD 77% vs. 39% 81% vs. 19%
Progression to cancer 13% vs. 28% 2.4% vs. 19%
Stricture 36% 6%
Adapted from Wolfsen.4
Table 3. Diseases with cancer-prone epithelium and operations designed to reduce cancer risk
Study n Modality Outcome Follow up Complications
Pech et al.3 349 EMR (255) EMR + PDT (11) Long-term complete response 95% 64 months 17%
5-year survival 84%
Pouw et al.8a 82 EMR + RFA CR-N 100%, CR-IM 93% 12 months 13%
aEuro II study: interim analysis of ongoing prospective multicenter trial.
Figure 1. Current optimal approach to endoscopic treatment
of early Barrett’s cancer.
can be safely performed to semi-circumferential,
2 cm in length areas. ER is repeated until all en-
doscopically visible abnormalities are removed. The
residual Barrett’s mucosa should then be eradi-
cated given the risk of developing metachronous
lesions.
RFA is the preferred ablation modality in BE
following ER of visible mucosal lesions or in flat
dysplasia. For long segments of Barrett’s mucosa
(>3 cm), balloon-based RFA (Halo 360) is pre-
ferred initially. For short segments or residual Bar-
rett’s following balloon ablation, probe-based RFA
(Halo 90) is recommended. Alternatively, ER can be
performed exclusively in those with short segments
of Barrett’s (<3 cm). The recommended approach
to endoscopic treatment of early Barrett’s cancer is
summarized in the following algorithm (Fig. 1).




In the last decade, several endoluminal devices have
gained attention as promising tools for treatment
of gastresophageal reflux disease (GERD) as an al-
ternative to laparoscopic fundoplication. However,
several requirements need to be met for them to
prove successful: they need to be safe, effective,
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Table 4. Summary results for endoluminal plication devices
Plicator (NDO) Rothstein 2006 78 3 m 50 23 Plicator
80 24 15 sham
Pleskow 2007 29 3 yrs 57 n/a
2008 33 5 yrs 67 n/a
EndoCinch (Bard) Abou-Rebyeh 2005 38 1 yr 20 14
Schiefke 2005 70 1.5 yrs 6 28
EsophyX (EGS) Cadière – Phase 1 2008 17 1 yr 82 63
2009 14 2 yrs 79 n/a
Cadière – Phase 2 2008 79 1 yr 85 37/48
2009 51 2 yr 71 n/a
user-independent, and economically viable. That
strong combination has yet to be seen and has
driven several of these devices to failure. As op-
posed to bulking agents, plication devices have made
further achievements by starting with the right
concept of recreating the anatomy of a valve at the
GE junction. But this concept is far from being a
simple task and technical challenges have hampered
most of the attempts. The first plication device was
Endocinch (BARD, Inc., Murray Hill, NJ, USA),
which showed good initial control of symptoms but
lack of objective reflux control with PH monitor-
ing. The symptom control failed in the long-term
follow-up, plication seemed to be loosened, and this
procedure has been abandoned.8 With similar re-
sults but a mild improvement in reflux control the
Plicator (NDO Surgical, Inc., Mansfield, MA, USA)
has shown a better transmural fixation trying to
ensure serosa-to-serosa contact.9 However, a real
valve with a long esophageal segment could not be
achieved. This procedure has also been discontin-
ued by most of the surgical community. The most
recent device launched to the market is the Esophyx
(EndoGastric Solutions) that allows the creation of
a valve that resembles a laparoscopic fundoplication
with a high-pressure zone and interesting anatomi-
cal appearance. Initially reported results were more
encouraging than previous competitors and mixed
results started to appear as the technique spreads
out.10,11
A large clinical trial undergoing in the U.S. will
probably set faith for this approach. A summary of
available results for all these devices is reported in
Table 4. In order to accurately understand the re-
sults of the endoluminal plication procedures, we
need to analyze what the expectations were, what
we compared them to, and what the optimal patient
population is. Initially the stakes were set too high
as everyone thought of this as the perfect alternative
to withdraw patients from PPIs without the need of
undergoing a laporoscopic surgery and its known
side-effects. Comparison with laparoscopic surgery
is probably the wrong idea for these devices, as we
have learned that hiatal hernias are a big limitation
for these procedures. If there is a room for an en-
doluminal procedure, it will be in a middle-world
between chronic medication and the Nissen fundo-
plication. Therefore, comparisons should be made
with medical therapy.
And last but definitely not least, patient selec-
tion will turn out to be the key if any endoluminal
plication will survive. In a retrospective study, Kha-
janchee et al. showed that patients with lower De-
Meester scores, heartburn scores lower than 2, and
body mass index lower than 30 had a significantly
better outcome when undergoing an endoluminal
plication.
This tendency shows that only a highly selected
population will benefit from these technologies
making the market still available but much less at-
tractive for the companies that need to work on
the evolution of these devices. This fact deserves a
paragraph on insurance carriers that are ever search-
ing for ways to reduce medical costs, and they are
very cautious after the first iteration of endolume-
nal antireflux procedure and require concrete evi-
dence of efficacy prior to authorizing payment for
these novel procedures. George Bernard Shaw said
“When I was a young man I observed that nine out
of ten things I did were failures. I didn’t want to
be a failure, so I did ten times more work". This
seems to be the case if we want to find a safe,
effective and reliable endoscopic method for our
patients.
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3. May endoscopic ablation therapies
induce formation of cells more susceptible
to genomic damage?
Katerina Dvorak and Aaron Goldman
kdvorak@email.arizona.edu
BE is a premalignant condition associated with the
development of EAC. Patients with this cancer have
a poor prognosis with a median survival of less
than one year. It is becoming clear that acid sup-
pression therapies alone, using surgery or drugs,
have no significant effect on reversing BE. Endo-
scopic ablation therapies are becoming more popu-
lar in recent years, especially for patients with HGD
or with intramucosal adenocarcinoma. Endoscopic
ablation of abnormal tissue is less invasive and safer
compared to esophagectomy that used to be the
only routine clinical treatment of HGD and EAC.
A number of endoscopic therapies to eradicate
esophageal columnar epithelium were developed
over recent years including APC, multipolar elec-
trocoagulation, PDT, laser therapy, cryotherapy, and
RFA. However, concerns remain regarding incom-
plete ablation, strictures, and buried glands that are
not readily detected and may represent a risk for
esophageal cancer development.
In the setting of complete ablation, the neosqua-
mous epithelium is not different from normal squa-
mous epithelium and represents low cancer risk.
Garewal et al. have shown low expression of Ki67,
p53, and low activities of ornithine decarboxylase
in new squamous epithelium in completely ablated
esophagus.12 Furthermore, new squamous epithe-
lium exhibits low level of staining for Ki67 and p53
as well as no DNA abnormalities after RFA. Cytok-
eratin expression (CK-8 and-14) and miRNAs were
also similar in postablation neosquamous epithe-
lium and normal squamous epithelium.
However, in the setting of incomplete ablation the
data are not so clear. Krishnadath et al. reported that
three patients who were free of dysplasia after photo-
dynamic therapy developed dysplasia during follow-
up and also had increased expression of at least one
of the markers associated with increased cancer risk
(Ki67, aneuploidy, p53 expression, or p16 promoter
hypermethylation).13 Similarly, Hage et al. found
that after ablation therapy, residual or recurrent
BE glands retain or accumulate abnormalities such
as p53 overexpression, increased proliferation, and
DNA abnormalities even in the absence of dyspla-
sia.14 In contrast, a recent biomarker study by Prasad
et al. shows that DNA abnormalities detected by
fluorescence in situ hybridization (FISH) were sig-
nificantly decreased after PTD therapy. However, a
subset of patients (19%) without dysplasia had pos-
itive FISH results and developed recurrent HGD.15
Hornick et al. reported that buried glands after PDT
show reduced crypt proliferation and lower level
of DNA abnormalities, and they suggest that these
glands have lower neoplastic potential.
The majority of these studies evaluated only biop-
sies of columnar epithelium from incompletely ab-
lated patients. Only few studies evaluated changes
in squamous epithelium after ablative therapies
and only few patients were included in these stud-
ies. Furthermore, even fewer studies were focused
on biomarker alterations at new squamo-columnar
junctions that are formed after incomplete ablation.
Our group has shown that these new junctions stain
positively for several cancer risk associated biomark-
ers, such as cyclooxygenase 2, Ki67, and p53 in a sub-
set of patients.16 Importantly, the expression of these
biomarkers was low in the preablation BE biopsies.
The major approach to eradicate BE is combina-
tion of injury by different ablative techniques and
acid suppression. In this environment, intestinal
epithelium is healed and replaced primarily with
neosquamous epithelium; however, the effect on
cancer risk remains unknown, and the question
of whether ablation decreases the cancer risk re-
mains unanswered. Wound healing that follows ab-
lation is a complex process that involves different cy-
tokines, enzymes and growth factors, and activation
of signaling pathways. This process can be divided
into inflammation, proliferation, and maturation
phases. After injury, inflammatory cells invade the
wound tissue. They produce proteinases, reactive
oxygen species, and reactive nitrogen species as a de-
fense against bacteria. Inflammatory cells are also an
important source of growth factors and cytokines,
which initiate the proliferative phase of wound re-
pair. Wound healing is associated with increased
expression of IL-1, IL-1, IL-6, TNF-, or hep-
atocyte growth factor (HGF) and members of the
epidermal growth factor (EFG) family. Importantly,
overexpression of these cytokines and growth factors
and their receptors is often found in BE and EAC
and is likely to have a role in esophageal tumori-
genesis. Furthermore, reactive oxygen species pro-
duced by inflammatory cells can cause DNA damage
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resulting in mutations. Most of the genes that or-
chestrate the wound-healing process are also impor-
tant regulators of cancer growth and progression.
Therefore, epithelium undergoing these changes is
possibly more prone to genomic instability and is
susceptible to DNA damage in a subset of BE patients
especially those, who require repeated ablation. In
addition, DNA damage and increased cytokine and
growth factor expression may even be elevated if
acid and bile reflux is not well controlled. Indeed,
both these components of refluxate were shown to
induce DNA damage.
In summary, it is not clear if ablative therapies
reduce cancer risk. In susceptible BE patients, they
may induce formation of cells with damaged DNA
and mutations and, thus, with higher risk to develop
EAC. Additional markers that have been reported to
be abnormal in Barrett’s intestinal metaplasia and
EAC deserve to be studied to further address this
important clinical issue.
4. What can be expected from Banding
without-resection for Barrett’s esophagus?
Edgardo Diaz-Cervantes
edgardoscopio@hotmail.com
Most of the ablative treatments for Barrett’s esoph-
agus are expensive, potentially hazardous, require
specialized training, and are not universally avail-
able. Furthermore, these ablative techniques may fail
to eradicate all of the Barrett’s epithelium and often
leave remnants of metaplastic mucosa behind in the
form of visible islands or in the form of glands buried
under a layer of neosquamous epithelium.17 An ef-
fective ablative therapy for BE that is relatively in-
expensive, safe, simple, and readily available would
be highly desirable. We have been working on BWR
from April 2004 to date (seven years); this work has
been formerly published in 2007.18
BWR is a new ablation modality that probably
collects the above desired criteria for an ideal abla-
tive technique. It is simple, because there is no need
for special skills—you just need an endoscope, a
multiband ligator, and some technique; there is no
need for an injector, snare, or anything else. BWR
is also very effective: during the last seven years we
have gotten rid of Barrett’s in 110 patients, by band-
ing one or two spots of Barrett’s epithelium on each
session and repeating at three month intervals un-
til the metaplastic epithelium has been completely
eradicated. We have obtained 98% of complete res-
olution of intestinal metaplasia compared to only
2% in our control group consisting of 76 patients
(with omeprazol bid for years, only). BWR is a
minimally invasive and “easy” procedure for the
esophagus because only a very small, superficial
Figure 2. This C1M3 BE was completely ablated in just 2 sessions and 3 rubber bands. The image is enhanced by magnification
and acetic acid.
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ulceration must heal—the residual scar is thin,
small, superficial, and this is probably the main rea-
son for the absence of residual stenosis. BWR is not
expensive and is available worldwide. This new Bar-
rett’s ablation technique is “low tech” but has “high
results.”
Number of banding and sessions for complete
resolution of BE
How many banding sessions were needed to get
complete resolution of BE in the treated group con-
sisting of 101 SSBE and 9 LSBE segment Barrett’s?
A mean of 2.6 sessions (very similar to other abla-
tion procedures). How many bands were needed for
complete resolution of BE in these patients? A mean
of 4.7 bands.
Long-lasting changes
One of the big concerns after any ablation proce-
dure is what happens years after ablation and how
durable the changes are. In our 110 ablated patients,
posteradication changes seems to be durable. The
longer follow up in 44 of our 110 patients ranges
between 50 and 70 ms with permanent or durable
changes. After the last banding procedures, there is
no modification at all, on the endoscopic finding
even after four to six years (Fig. 3).
Comparison between techniques
A frequent inquiry about BWR is the lack of tissue
sampling after ablation; the answer to this is that ab-
lation modalities do not enable tissue sampling af-
ter ablation because, except for endoscopicmucosal
resection, all of them are in situ tissue-destroying
techniques. BWR has a deeper penetration mech-
anism, the same as endoscopic mucosal resection
EMR (submucosal), whereas other ablation proce-
dures affect only the mucosal layer. Because of its
mechanism of action, this nonresection technique
avoids the risk of perforation and bleeding (Fig. 2).
Conclusions
(1) BWR is a new ablation procedure for Barrett’s
and is very different than EMR.
(2) BWR has the potential to remove HGD because
it achieves good depth of ablation.
(3) BWR has many advantages and appears to have
fewer risks than EMR and other ablative modal-
ities because it is minimally invasive (“easy” on
the esophagus).
(4) In our 110 patients, we found no complications
at all (no stricture, bleeding, or perforation),
and 98% complete resolution of intestinal meta-
plasia.
(5) BWR may be the procedure of choice in cir-
rhotic patients with BE and HGD
Figure 3. The same patient as shown in Fig. 2 one year after 2 banding sessions and 3 rubber bands. There is no stenosis at all.
Four years of follow up has demonstrated no further changes, with apparent BE endoscopically and histologically cleared.
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(6) Posteradication changes seem to be durable
even after six years of follow-up.
BWR appears to be a safe, effective, simple, and
widely available technique for eradicating short-
segment and tongued large-segment BE. Neverthe-
less, further studies are needed.
5. How should complete ablation of
Barrett’s mucosa be defined?
Melissa P. Upton
mupton@u.washington.edu
Before defining “complete ablation of Barrett mu-
cosa,” it is essential to acknowledge that there is still
no international agreement regarding the definition
of Barrett mucosa. What are we trying to ablate?
The original definition by Mr. Norman Bar-
rett was columnar lining of the tubular esopha-
gus, and it dominated the thinking of physicians
and scientists for decades. It remains the definition
in England and in some other countries, includ-
ing Japan. According to this definition, esophageal
columnar lining can include any type of colum-
nar metaplasia—oxyntic, cardiac, and intestinalized
mucosae. This would also include multilayered ep-
ithelium, a hybrid epithelium identified more re-
cently and seen in association with chronic re-
flux. Using this definition, complete ablation would
require ablation of all columnar lining in the
esophagus.
In contrast, the American definition of Bar-
rett’s esophagus, adopted in the mid-1990s, requires
an endoscopic–histologic correlation. The endo-
scopist must recognize irregular tongues of pink
columnar-appearing epithelium extending into the
esophagus proximal to the GE junction, and the
pathologist must confirm the histologic finding of
specialized columnar epithelium, intestinalized ep-
ithelium with goblet cells containing acidic mucins,
in biopsies designated as esophageal in location.
The American definition came into use following
the recognition that the overwhelming majority of
cases of EAC and high-grade glandular dysplasia
occurred in a setting of columnar metaplasia with
goblet cells detected on biopsy. Using the Ameri-
can definition, if the goal is ablation of all Barrett
mucosa, we would theoretically ablate the colum-
nar lining of the esophagus only in patients with
histologically documented goblet cells.
One problematic issue with the American defini-
tion is the challenge of sampling, because goblet cell
distribution may be extensive, or focal and patchy.
Occasionally, many biopsies may be needed to iden-
tify goblet cells, especially in patients with extensive
neoplastic alterations. Although the Seattle protocol
of biopsy sampling has been recommended as the
standard approach, it is clear from a review of prac-
tice settings that many gastroenterologists do not use
large-jaw biopsy forceps or take the recommended
numbers of biopsies at the prescribed distance in-
tervals between biopsies outlined in this protocol.
In addition, both in historic mapping series and in
more recent studies of endoscopic mucosal resec-
tion specimens, cases of adenocarcinoma have been
reported in a setting of columnar lined esophagus
without histologic documentation of goblet cells.
The epithelium adjacent to and in carcinomas may
not have identifiable intestinal phenotype. In addi-
tion, aneuploidy, and cell cycle abnormalities have
been reported in epithelium without histologic fea-
tures of neoplasia.
It is likely that intestinal metaplasia is simply a
histologic marker of risk. Neoplastic changes prob-
ably arise in a mutated stem cell population with the
capability of differentiating into a neoplastic clone
with or without histologically recognizable intesti-
nal phenotype or acidic mucin production. In ad-
dition, there may be important contributions to the
development of neoplastic risk by stromal compo-
nents and by populations of the submucosal glands
of the esophagus.19 Ablation limited to the mucosa
or superficial epithelium and lamina propria may
not be adequate. To confirm if endoscopic ablative
techniques can eradicate the risk of future neoplasia,
will require longer follow-up intervals, rigorous and
careful postablation surveillance biopsies, and addi-
tional investigation into the molecular mechanisms
of neoplastic development. More work is needed to
identify the cells of origin and the permissive mi-
croenvironment that favors neoplasia.
In addressing the issue of complete ablation, what
are we trying to ablate? Is the goal to ablate neo-
plastic mucosa? Presumably, the goal is not to sim-
ply ablate already detectable neoplastic epithelium,
but also to ablate mucosa that is at risk for fu-
ture neoplastic alterations. Will we refer only pa-
tients with documented goblet cells, associated with
higher risk for malignancy in the American se-
ries? Will we include patients with any columnar
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lining of the esophagus, given recent EMR data
suggesting that neoplasia may develop in cardiac
mucosal background?
Some investigators have suggested that all patients
with Barrett’s esophagus are potentially at risk for
neoplasia and should be considered for ablation of
the entire columnar lining. But ablation is costly,
and patients will require continued surveillance af-
ter ablative treatment. Therefore, any decision for
mucosal ablation must balance the potential costs
and risks of the procedure and continued surveil-
lance with the benefits of ablation. Instead of ab-
lating all patients with Barrett’s mucosa, perhaps
we should treat only selected groups within the
large population of patients with BE, treating only
those with histologically proven neoplasia or those
who show specific molecular markers for increased
risk of progression, such as aneuploidy or increased
synthetic fraction when studied by DNA flow
cytometry.
Future studies are needed to address whether
molecular markers, such as methylation or mutation
of p16, can assist in selection of patients at increased
risk for neoplasia for whom ablation is clearly in-
dicated. And we must design robust and thorough
methods of follow-up for treated patients, both to
avoid missing neoplasms that may develop in the
postablation period, and also to gain understanding
of how the esophagus and its microenvironment
(including molecular events) are altered by abla-
tion procedures, and if this alters the risk for future
neoplastic changes.
6. Can the factors of recurrence of




This can be paraphrased to this question: once Bar-
rett’s mucosa is destroyed by any type of ablation,
and it recurs, is there an explanation for the recur-
rence? To answer this question, we need data from
a study that begins with Barrett’s mucosa, which
is then ablated by any technique and replaced by
new squamous epithelium. Then the study design
has to find a way to prove unequivocally that the
Barrett’s has been completed destroyed, and that
no residual Barrett’s mucosa is present beneath the
new squamous mucosa, presumably by biopsy of
the entire previous Barrett’s segment. The study
then must continue with extensive follow-up, and in
those cases in which the Barrett’s mucosa recurs, the
study must identify the reasons for the recurrence.
I looked everywhere for this study, and I could not
find it. So I looked for published hints.
In one study of 72 patients with 2–6 cm of
Barrett’s mucosa treated with radio frequency ab-
lation, 92% achieved complete response with no
recurrence at five years.20,21 The definition for com-
plete response was the lack of residual intestinal
metaplasia in any biopsy. The biopsy protocol in-
volved four quadrants at every level in one to two
centimeter increments, which clearly left a lot of
esophageal mucosa not sampled. 8% of these pa-
tients did not have a complete response, possibly
indicating recurrence in some patients. However,
no factors were evaluated in this 8% to help me
answer the question above.
In another study on laser ablation in 31 pa-
tients, 21 achieved complete response, which was
not clearly defined in the study, but presumably it
was lack of intestinal metaplasia on any biopsy.22
Unfortunately, the biopsy protocol was not defined.
Eight patients had recurrence of Barrett’s from 6
to 44 months after presumably successful ablation,
and six of these had a colonic epithelial protein
antigen in cardiac-type epithelium without goblet
cells, the Das antigen suggesting that this protein
is a reasonable predictor of recurrence. However,
the antigen was expressed in cardiac-type mucosa,
often buried under squamous mucosa, not in gob-
let cell–containing mucosa. In the British definition
of Barrett’s mucosa, this cardiac-type mucosa with
the Das antigen would have been considered Bar-
rett’s mucosa if there were appropriate endoscopic
findings.
One likely explanation for recurrent Barrett’s mu-
cosa is that this mucosa has become covered by
metaplastic squamous epithelium induced by the
ablation technique, and this hid residual Barrett’s
from endoscopic detection and from biopsy. No
study can guarantee that this has not happened,
because no study followed ablation with biopsy of
the entire previous Barrett’s segment. Another ex-
planation is that Barrett’s recurred, because the new
squamous epithelium induced by ablation is subject
to the same factors that caused the Barrett’s mucosa
to occur originally. If we only knew how Barrett’s
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developed in the first place. Unfortunately, we do
not.
To summarize, can the factors of recurrence of
Barrett’s mucosa after ablation be defined? The
answer is not yet, but we should keep trying. How-
ever, first we have to define the difference between
recurrence and hidden residual Barrett’s mucosa.
7. Is the combination of APC with




BE is defined as a biopsy-proven change in the dis-
tal esophageal epithelium, with normal squamous
epithelium being replaced by columnar epithelium
containing goblet cells. This condition, also known
as intestinal metaplasia, occurs in approximately
10% of patients with gastroesophageal reflux dis-
ease.23 Intestinal metaplasia is a premalignant con-
dition associated with an increased risk of EAC es-
pecially when LGD or HGD is found in the biopsies.
On the other hand, molecular alterations may even
precede the development of intestinal metaplasia in
BE.24
Retrospective studies have demonstrated that pa-
tient survival is improved if an endoscopic surveil-
lance strategy detects cancer at earlier stages com-
pared to a strategy of no surveillance.25 However,
surveillance is a strategy designed to detect cancer,
not to prevent cancer. Over the past decade, research
efforts have been directed toward endoscopic mu-
cosal ablation to eliminate the risk of cancer and
allow regeneration of squamous epithelium follow-
ing pharmacological or surgical control of reflux.26
The clinical value of endoscopic ablation of nondys-
plastic BE combined with acid suppression therapy
or antireflux surgery remains controversial.
APC, at a power output of 60–90 Watts, allows
a safe ablation of BE and LGD with a high suc-
cess rate. In our series including 94 patients with
nondysplastic BE, the eradication rate was 72.3%
with an average of three treatment sessions. Of the 68
eradicated patients, 27 underwent fundoplication
and 41 were treated with proton pump inhibitors;
the eradication rate was 89.4% and 87.5%, respec-
tively, with a mean follow-up of 26 months. 27 Bright
et al. recently published the results of a randomized
trial of APC versus endoscopic surveillance for BE
after antireflux surgery. Regression of BE after fun-
doplication was more likely, and greater in extent, in
patients who underwent prior ablation with APC.
Moreover, in most patients treated with APC, the
newly developed squamous epithelium remained
stable at up to five-years follow-up. The only case of
progression to HGD occurred in a patient who was
not treated with APC before surgery.28
8. Optimizing techniques for RFA
to treat BE
Richard I. Rothstein, MD
richard.i.rothstein@hitchcock.org
Attention to radiofrequency device evolution and
procedural techniques, along with individualized
patient factors, will permit optimization of out-
comes from this innovative and beneficial therapy
for BE. RFA is optimal for treating flat, nonnodular
BE. Individuals with nodular disease may be treated
with RFA following the removal of the nodular seg-
ments with endoscopic mucosal resection (EMR).
A delay of six to eight weeks between the time of
EMR to the performance of RFA of Barrett’s tis-
sue should provide adequate time for healing of the
resected mucosa and is necessary for the best treat-
ment outcomes. RFA is a safe and effective treatment
for dysplastic Barrett’s as well as intestinal metapla-
sia with foci of intramucosal carcinoma (staged by
endoscopic ultrasound and EMR). Selected nondys-
plastic Barrett’s patients can be safely and effectively
treated with RFA and it can be cost-effective for
the management of that condition compared to the
surveillance strategies in current practice.
The performance of RFA involves the use of spe-
cialized devices and a sophisticated control unit
(Halo 360 and 90, Barrx Medical). With the Halo
RFA system, thermal energy is precisely delivered to
the treated tissue to a depth of 500–1000 m, to
remove the mucosal layer and limit damage to the
deeper submucosal layer. That effectively reduces
the problem of stricture formation, which is a ma-
jor problem with other ablation treatments such as
wide-field EMR and PDT.
The Halo 360 system uses a sizing balloon catheter
and variable-sized electrode treatment balloons.
The procedure is done following a standard up-
per endoscopic exam during which the landmarks
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are recorded for the upper border of the Barrett’s
segment and the top of the gastric folds as well as
the geographic pattern of the intestinal metapla-
sia. The Barrett’s segment is cleaned with a spray
of dilute n-acetylcysteine to remove surface mucous
and a guidewire is left in the distal stomach as the
gastroscope is removed. Over this guidewire, the siz-
ing balloon is passed and localized 12 cm proximal
to the top of the gastric folds (placed even higher
if needed to be above the proximal extent of the
Barrett’s for ultra-long segment disease). Stepwise
inflation and deflation of the balloon as it is moved
centimeter-by-centimeter towards the cardia allows
the determination (shown on the digital monitor
of the control unit) of the size of the esophageal
lumen, which is used to determine the effective
treatment balloon size. In the situation of multi-
ple balloon sizes recorded along the length of the
esophagus, the recommendation is to use the small-
est treatment balloon size recommended. However,
in the situation of smaller proximal lumen and a
consistently larger distal lumen, as may be seen in
longer-segment disease, it is appropriate to use a
smaller treatment balloon proximally and the larger
size distally. In all situations, it is important to view
that the selected treatment balloon size permits ef-
fective contact of its electrodes to the esophageal
wall.
After the sizing steps have been completed, the
sizing balloon is removed and the selected treat-
ment balloon is introduced over the guidewire. The
gastroscope is introduced alongside the Halo 360
catheter since the RFA treatment is done under
direct vision. The proximal part of the electrode
segment of the treatment balloon is best placed 1
cm proximal to the top of the Barrett’s segment.
For Barrett’s with dysplasia, the setting for abla-
tion is typically set on the unit at 12 joules/cm2,
whereas for nondysplastic it is recommended to be
10 joules/cm2. The Barrett’s segment is treated prox-
imal to distal with a 5 mm to 1 cm overlap in order
to obtain uniform treatment without “skip” areas.
Once treated, the endoscope and the balloon with
guidewire are all removed from the patient. A soft
sort distal cap is placed on the gastroscope, which
is reintroduced and used to scrape away all of the
treated sloughing mucosa. This step is very impor-
tant to optimize the ablation outcome, and enough
time should be spent to ensure adequate cleaning
of the treated segment. The guidewire is replaced
Figure 4. Halo 360 postablation view.
into the stomach and the endoscope removed. The
treatment technique of balloon passage and use is
repeated as described, with all of the Barrett’s seg-
ment treated a second time. Following removal of
the endoscope, balloon, and guidewire, the patient
is recovered, and instructed to continue on bid pro-
ton pump inhibitors and to consume a liquid diet
for two days and then a soft diet for three to five days
before resuming a regular diet. Mild analgesics may
be needed, and patients should be given instructions
and education about the typical sensations to expect
following the RFA treatment (Fig. 4).
In follow-up RFA sessions where there may be
residual small areas of Barrett’s remaining after the
circumferential balloon treatment, the Halo 90 sys-
tem may be employed. This endoscope-mounted
system, with an electrode pattern of 13 × 20 mm,
can also be used for primary therapy of short seg-
ment disease. After a standard upper endoscopy, the
Halo 90 device is mounted on the endoscope which
is reintroduced and used in a patchwork fashion
with 3 mm overlap onto treated segments to treat
all areas of intestinal metaplasia. In contrast to the
single application of thermal energy with the cir-
cumferential balloon, followed by cleaning of the
segment and then retreatment, with the Halo 90 the
Barrett’s mucosa is treated twice, then scraped clean,
and then retreated. Instead of a cap, the mounted
RFA device can be used for removal of the sloughed
tissue. When treating short segment disease, the de-
vice is placed to straddle the top of the gastric folds,
and the treatments done by rotating the scope to
permit an overlap of a few millimeters and moving
150 Ann. N.Y. Acad. Sci. 1232 (2011) 140–155 c© 2011 New York Academy of Sciences.
Saunders et al. Barrett’s esophagus: endoscopic treatments I
around the gastroesophageal junction, usually tak-
ing six treatment sites to cover the circumference.
Posttreatment recommendations are as for the cir-
cumferential treatment described.
As for all new advanced endoscopic procedures,
adequate training and mentoring are essential to
optimize the clinical outcomes and ensure the best
safety for RFA of Barrett’s. For references to this
section, see Refs 6, 21, 29, 30 and 31.
9. Ablation of nondysplastic Barrett’s
epithelium: a surgeon’s perspective
Vic Velanovich
vvelano1@hfhs.org
Ablation of BE has been shown to be an effec-
tive means of eliminating Barrett’s epithelium32
and to decrease the incidence of EAC in patients
with HGD.6 Nevertheless, controversy exists as to
whether or not ablating nondysplastic Barrett’s ep-
ithelium should be done.22 This paper provides the
surgeon’s perspective on this issue.
The concept of eliminating cancer-prone epithe-
lium is not new to surgeons. There are several dis-
ease processes which have had operations designed
specifically to reduce cancer risk (Table 5). There-
fore, it is not a conceptual leap for the surgeon to
apply ablative techniques to Barrett’s epithelium to
reduce cancer risk.
Although the risk of EAC in BE is low, prevention
is still worthwhile due to the serious consequences
of developing adenocarcinoma. EAC is primarily
treated with esophagectomy. Esophagectomy car-
ries significant and not easily ignored immediate
Table 5. Diseases with cancer-prone epithelium and op-
erations designed to reduce cancer risk
Disease Operation
Colonic adenoma Colonoscopy polypectomy















and long-term adverse events. In the short-term,
even in the best of hands, the morbidity rate is
over 50%, with a measurable mortality rate. In gen-
eral practice, the mortality rate can be as high as
10%. Stricture at the anastomosis can occur in 25–
50% of patients. This not only leads to dysphagia,
but may require multiple dilations. Long-term, even
with curative surgery, the quality of life effects of an
esophagectomy are substantial. Djarv et al.33 have
shown that three years after curative esophagectomy
for esophageal cancer, patients have lower quality of
life score compared to population norms in several
physical functioning domains as well as several con-
stitutional symptoms. Therefore, prevention of an
esophagectomy is almost as worthwhile goal as the
prevention of adenocarcinoma. In many respects,
ablation of Barrett’s epithelium can be considered a
means of preventing esophagectomy.
BE can recur after ablation. This is prevented by
a strict regimen of acid-suppression therapy. How-
ever, the development of Barrett’s is promoted most
aggressively by the combination of acid and bile re-
flux. Although proton pump inhibitor therapy is
effective in reducing acid reflux, it does nothing for
bile reflux. We have previously shown that the ad-
dition of an antireflux operation, most typically a
laparoscopic Nissen fundoplication, reduces the rate
of recurrent or persistent BE.34 Clearly, a random-
ized trial is needed to confirm these findings.




Perhaps the most intriguing aspect of endotherapy
for BE is its application in nondysplastic disease. Al-
though offering therapy for patients with dysplastic
BE is a cost-effective strategy, the same is not so
evident for nondysplastic disease. However, treat-
ing only patients with dysplasia will likely limit our
ability to reach the ultimate goal of eradication of
EAC.
RFA offers an effective, safe, and durable treat-
ment for patients with BE. Most recently, five years
data from the AIM II trial demonstrated 92%
complete eradication of BE (CR-IM). This is ex-
tremely exciting data and encourages to expand our
indications for endotherapy in BE. Although RFA
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in nondysplastic BE appears to be cost-effective if
surveillance can be discontinued, it remains to be
seen where this fits in the management paradigm
when surveillance is continued.
Currently, there is insufficient data to recommend
cessation of surveillance after endotherapy despite
achieving CR-IM. A potential solution is to risk-
stratify our patients with BE for consideration for
RFA. Although many biomarkers are under inves-
tigation, we are still far from a simple blood test to
define risk in nondysplastic BE. That being said, we
currently have a safe therapy that can eliminate not
only disease, but any of these molecular changes that
may drive stem cell differentiation. In addition, we
must consider quality of life (QOL) in this cohort.
It is considered standard of care to eliminate all pre-
cancerous lesions in the body (e.g., colon polyps,
breast lumps, and actinic keratosis). This paradigm
creates a dilemma when we tell our patients that we
will not remove their precancerous BE. It is difficult
for patients to consider the small rate of progression
to cancer in these circumstances. Therefore, we must
consider how this would affect a patient’s quality of
life when making treatment decisions. Previous data
have shown incremental improvement in QOL with
successful eradication of BE. Ultimately, it would be
ideal to have data that demonstrates a true cancer
reduction with implementation of RFA as a treat-
ment strategy in nondysplastic BE. However, given
the progression rate, this will likely not be feasi-
ble any time soon. Despite the lack of this data,
the durability of RFA and a recent meta-analysis
clearly suggests that implementation of RFA would
decrease the incidence of EAC.
Currently, RFA should be considered in select pa-
tients who fully understand the limitations of cur-
rently available data. These may include patients
who are young (age <50), those with long seg-
ment disease, and patients with family history of
BE-dysplasia or EAC. Regardless of this choice, it
is imperative to have an extensive discussion with
these patients and discuss the current data to al-
low them to make an educated decision about
their disease. [For references to this section, see
Refs 35-38]
11. What is the mechanism of regression
of Barrett’s esophagus after BWR?
Edgardo Diaz-Cervantes, A. De-la-Torre-Bravo,
S. Sobrino-Cossio, E. Torres-Durazo,
O. Martı́nez-Carrillo, and J. Gamboa-Robles
edgardoscopio@hotmail.com
Because Barrett’s epithelium has a thickness of only
0.5 to 0.6 mm,39 banding might be expected to result
in its complete eradication. Indeed, an event in our
endoscopy unit revealed an ablative technique for
Barrett’s esophagus (BE) that could fulfill a num-
ber of the ideal criteria for an ablative alternative.
During an endoscopic variceal ligation in a patient
who had bleeding esophageal varices, we placed a
band on a varix that had an overlying tongue of BE.
Proton pump inhibitors were prescribed. To our
surprise the BE was no longer visible on a follow-up
endoscopic examination one month later; this ob-
servation suggested that banding had eradicated the
BE.18
Figure 5. Methods of ablation.
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Figure 6. Banding without-resection.
Banding without-resection (BWR) is a novel
method of ablation for BE, consisting on the cre-
ation of a pseudopolyp by using a multib and lig-
ation device. Its main feature resides in a non-
resection technique of the created pseudo-polyp,
leaving it just ligated until it spontaneously sloughs
off (Fig. 5), leaving a small ulceration that heals with
neosquamous epithelium.
Mechanism of regression
1. Ischemia: the band obliterates the blood flow,
and 5 to 10 days later the ischemic tissue sloughs
off, leaving a small ulceration that heals with
the replacement of neosquamous mucosa when
acid reflux is controlled by the administration
of PPI.
2. The defect of the banded mucosa is replaced
by surrounding mucosa. This means that the
smaller mucosal defect leads to smaller residual
ulcer, resulting into a small, thin, and superficial
scar.
2. By BWR, we don’t snare, cut, heat; we neither
infiltrate nor inject; we just apply suction, band,
wait, and follow-up . . . so simple . . . so “easy”
on the esophagus.
One drawback of BWR is that there is no tissue
for histological evaluation; but this is a drawback
shared by all ablative in situ-destroying procedures
for BE, except for EMR (Fig. 6).
Depth of ablation
Because BWR depends on the creation of a
pseudopolyp, and the same principle rules for en-
doscopic mucosal resection (EMR): then, both pro-
cedures may have similar depth of ablation. En-
doscopic banding has an excellent track record of
safety, even in high risk patients with cirrhosis.
There are many substantial advantages on BWR
when compared to resection, such as:
1. Banding without-resection is per se preventive
for bleeding and perforation.
2. No need for submucosal injection before band-
ing.
3. The risk of stricture after banding without-
resection is minimal or absent. As a result of
BWR we obtain only a thin, small and super-
ficial scar, instead of big mucosal defects with
long and gross scars that are usually obtained
after resection.
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